Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07688577Phase 1Not Yet Recruiting

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

Role: lead

NCT05684965Phase 1Recruiting

XTX301 in Patients With Advanced Solid Tumors

Role: lead

NCT04896697Phase 1Completed

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Role: lead

NCT05052268Phase 1Completed

XTX202 in Patients With Advanced Solid Tumors

Role: lead

All 4 trials loaded